4ONG
Fab fragment of 3D6 in complex with amyloid beta 1-40
Summary for 4ONG
| Entry DOI | 10.2210/pdb4ong/pdb |
| Related | 4ONF |
| Descriptor | 3D6 FAB ANTIBODY HEAVY CHAIN, 3D6 FAB ANTIBODY LIGHT CHAIN, Amyloid beta A4 protein, ... (7 entities in total) |
| Functional Keywords | antibody, amyloid beta peptide, immune system |
| Biological source | Mus musculus (mouse) More |
| Cellular location | Membrane; Single-pass type I membrane protein: P05067 |
| Total number of polymer chains | 3 |
| Total formula weight | 54789.84 |
| Authors | Feinberg, H.,Saldanha, J.W.,Diep, L.,Goel, A.,Widom, A.,Veldman, G.M.,Weis, W.I.,Schenk, D.,Basi, G.S. (deposition date: 2014-01-28, release date: 2014-06-11, Last modification date: 2024-11-27) |
| Primary citation | Feinberg, H.,Saldanha, J.W.,Diep, L.,Goel, A.,Widom, A.,Veldman, G.M.,Weis, W.I.,Schenk, D.,Basi, G.S. Crystal structure reveals conservation of amyloid-beta conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res Ther, 6:31-31, 2014 Cited by PubMed Abstract: Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer's disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the preferred epitope or conformation of amyloid-β to target for treatment, and the mechanism of action underlying immunotherapy. Bapineuzumab (humanized 3D6), a neo-epitope specific antibody recognizing amyloid-β1-5 with strong preference for an exposed Asp residue at the N-terminus of the peptide, has undergone advanced clinical testing for treatment of AD. PubMed: 25024748DOI: 10.1186/alzrt261 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.2 Å) |
Structure validation
Download full validation report
